Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.64
RHHBY's Cash to Debt is ranked higher than
62% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. RHHBY: 0.64 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 0.64

Equity to Asset 0.34
RHHBY's Equity to Asset is ranked higher than
51% of the 754 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RHHBY: 0.34 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.59
Current: 0.34

0.1
0.59
F-Score: 8
Z-Score: 5.08
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 34.30
RHHBY's Operating margin (%) is ranked higher than
98% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.92 vs. RHHBY: 34.30 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 35.01
Current: 34.3

4.53
35.01
Net-margin (%) 23.15
RHHBY's Net-margin (%) is ranked higher than
96% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. RHHBY: 23.15 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 23.15

-13.67
30.16
ROE (%) 56.81
RHHBY's ROE (%) is ranked higher than
99% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. RHHBY: 56.81 )
RHHBY' s 10-Year ROE (%) Range
Min: -16.17   Max: 71.47
Current: 56.81

-16.17
71.47
ROA (%) 17.58
RHHBY's ROA (%) is ranked higher than
97% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. RHHBY: 17.58 )
RHHBY' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 17.58

-5.78
17.58
ROC (Joel Greenblatt) (%) 79.20
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.20 vs. RHHBY: 79.20 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9   Max: 84.52
Current: 79.2

6.9
84.52
EPS Growth (%) 8.60
RHHBY's EPS Growth (%) is ranked higher than
76% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. RHHBY: 8.60 )
RHHBY' s 10-Year EPS Growth (%) Range
Min: -3.8   Max: 343.8
Current: 8.6

-3.8
343.8
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

RHHBY Guru Trades in Q3 2013

Bill Frels 610,205 sh (New)
Ken Fisher 908,434 sh (+0.28%)
» More
Q4 2013

RHHBY Guru Trades in Q4 2013

Bill Frels 1,013,940 sh (+66.16%)
Ken Fisher 906,056 sh (-0.26%)
» More
Q1 2014

RHHBY Guru Trades in Q1 2014

Ken Fisher 1,803,070 sh (+99%)
Bill Frels 2,138,396 sh (+5.45%)
» More
Q2 2014

RHHBY Guru Trades in Q2 2014

Bill Frels 2,184,810 sh (+2.17%)
Ken Fisher 1,813,443 sh (-49.71%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Tweedy Browne 2013-06-30 Sold Out $28.92 - $32.98 $ 36.9520%0
Tweedy Browne 2012-09-30 Reduce -24.31%0.03%$20.95 - $24.07 $ 36.9565%62164
Vanguard Health Care Fund 2012-06-30 Add 543.36%2.96%$19.47 - $23.14 $ 36.9575%4273977
Tweedy Browne 2012-03-31 Reduce -22.19%0.04%$21.55 - $22.17 $ 36.9584%82130
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.30
RHHBY's P/E(ttm) is ranked higher than
88% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.30 vs. RHHBY: 21.30 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.29   Max: 52.91
Current: 21.3

13.29
52.91
P/B 11.18
RHHBY's P/B is ranked higher than
51% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. RHHBY: 11.18 )
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 22.21
Current: 11.18

2.64
22.21
P/S 5.08
RHHBY's P/S is ranked higher than
65% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. RHHBY: 5.08 )
RHHBY' s 10-Year P/S Range
Min: 2.21   Max: 6.44
Current: 5.08

2.21
6.44
PFCF 18.39
RHHBY's PFCF is ranked higher than
95% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 18.39 )
RHHBY' s 10-Year PFCF Range
Min: 8.19   Max: 39.65
Current: 18.39

8.19
39.65
EV-to-EBIT 14.81
RHHBY's EV-to-EBIT is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.17 vs. RHHBY: 14.81 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 14.81

7.9
32
Shiller P/E 24.48
RHHBY's Shiller P/E is ranked higher than
88% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.28 vs. RHHBY: 24.48 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.9   Max: 117.89
Current: 24.48

13.9
117.89
Current Ratio 1.85
RHHBY's Current Ratio is ranked higher than
65% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. RHHBY: 1.85 )
RHHBY' s 10-Year Current Ratio Range
Min: 1.55   Max: 3.75
Current: 1.85

1.55
3.75
Quick Ratio 1.48
RHHBY's Quick Ratio is ranked higher than
67% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. RHHBY: 1.48 )
RHHBY' s 10-Year Quick Ratio Range
Min: 1.28   Max: 3.22
Current: 1.48

1.28
3.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.00
RHHBY's Dividend Yield is ranked higher than
89% of the 489 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. RHHBY: 3.00 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 3.79
Current: 3

0.74
3.79
Dividend Payout 0.63
RHHBY's Dividend Payout is ranked higher than
75% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. RHHBY: 0.63 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.59
Current: 0.63

0.21
0.59
Dividend growth (3y) -7.30
RHHBY's Dividend growth (3y) is ranked higher than
72% of the 359 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. RHHBY: -7.30 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: -7.3

0
27.3
Yield on cost (5-Year) 2.46
RHHBY's Yield on cost (5-Year) is ranked higher than
75% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. RHHBY: 2.46 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 0.61   Max: 3.11
Current: 2.46

0.61
3.11
Share Buyback Rate -0.20
RHHBY's Share Buyback Rate is ranked higher than
82% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.20 vs. RHHBY: -0.20 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.39
RHHBY's Price/Tangible Book is ranked higher than
55% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. RHHBY: 23.39 )
RHHBY' s 10-Year Price/Tangible Book Range
Min: 4.05   Max: 95.2
Current: 23.39

4.05
95.2
Price/DCF (Projected) 2.16
RHHBY's Price/DCF (Projected) is ranked higher than
86% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.11 vs. RHHBY: 2.16 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.27   Max: 7.2
Current: 2.16

1.27
7.2
Price/Median PS Value 1.25
RHHBY's Price/Median PS Value is ranked higher than
72% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. RHHBY: 1.25 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.26
Current: 1.25

0.75
1.26
Price/Graham Number 4.66
RHHBY's Price/Graham Number is ranked higher than
71% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.82 vs. RHHBY: 4.66 )
RHHBY' s 10-Year Price/Graham Number Range
Min: 1.78   Max: 7.97
Current: 4.66

1.78
7.97
Earnings Yield (Greenblatt) 6.80
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
85% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. RHHBY: 6.80 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 6.8

3.1
12.7
Forward Rate of Return (Yacktman) 3.54
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. RHHBY: 3.54 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.2   Max: 210.8
Current: 3.54

4.2
210.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico
Roche was founded in 1896 and is headquartered in Basel, Switzerland and is a pharmaceutical and diagnostics company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. Roche also participates in in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management. Genentech, in the United States, and Chugai Pharmaceuticals are subsidiaries of the Roche Group. The firm's business is segmented into the dharmaceuticals business and the diagnostics Business.
» More Articles for OTCPK:RHHBY

Headlines

Articles On GuruFocus.com
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
Signature Select Canadian Fund's Top Holdings Jul 02 2014 
The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
Most Popular International Stocks of Investment Gurus Mar 05 2014 
John Rogers' Ariel Fund Comments on Roche Feb 28 2014 
Ariel International Fund & Ariel Global Fund - Healthy Ideas Feb 28 2014 
Tweedy Browne Global Value’s Top Five Year End Stocks Jan 24 2014 
Invesco European Growth Fund’s Top Five Jan 09 2014 


More From Other Websites
Bristol-Myers' Opdivo under Review in EU for Lung Cancer Oct 01 2014
Detailing Financial Links of Doctors and Drug Makers Sep 30 2014
Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment Sep 29 2014
Roche Releases Data from CLEOPATRA Study on Perjeta Sep 29 2014
Ahead of the Bell: Exelixis shares soar Sep 29 2014
Ahead of the Bell: Exelixis shares soar Sep 29 2014
Genentech’s Investigational Combination of Cobimetinib Plus Zelboraf (Vemurafenib) Provided... Sep 29 2014
2:19 am Roche Hldg unit Genentech's Perjeta regimen extended the lives of people with an aggressive... Sep 29 2014
Roche purchases shares in tender offer for InterMune, Inc. Sep 29 2014
Genentech’s Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic... Sep 28 2014
Roche Breast Cancer Drug Perjeta Appears to Greatly Extend Patients’ Lives Sep 28 2014
Roche Announces Positive Results from Studies on Avastin Sep 26 2014
Roche launches Global Access Program for HIV viral load testing Sep 25 2014
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer Sep 22 2014
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 Sep 18 2014
Roche Starts Trials on Lampalizumab for Geographic Atrophy Sep 16 2014
Why Roche (RHHBY) Stock Is Up Today Sep 16 2014
ACCU-CHEK® Aviva Expert, the first and only stand-alone blood glucose meter system with a built-in... Sep 16 2014
IBD 50 Names Hold Gains, But Actionable Charts Scarce Sep 15 2014
IBD 50 Names Hold Gains, But Actionable Charts Scarce Sep 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK